{"entity":{"id":"nct06359860","kind":"trial","name":"A Study of ST-1898 for Unresectable or Metastatic Melanoma","aka":[],"tldr":"A phase 1/2 trial of ST-1898 tablets in melanoma, run by Beijing Scitech-Mq Pharmaceuticals Limited, now recruiting.","summary":"A Study of ST-1898 for Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06359860 by Beijing Scitech-Mq Pharmaceuticals Limited, with 64 participants planned, started 2023-11-07 and due to reach its primary completion in 2026-12. Interventions recorded: ST-1898 tablets.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06359860","url":"https://clinicaltrials.gov/study/NCT06359860"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06359860","phase":"1/2","setting":"A Phase Ib/II Study to Evaluate the Efficacy and Safety of ST-1898 in Subjects With Unresectable or Metastatic Melanoma","sponsor":"Beijing Scitech-Mq Pharmaceuticals Limited","enrolled":64,"outcomes":[]},"route":"/trials/nct06359860/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"beijing-scitech-mq-pharmaceuticals","kind":"company","name":"Beijing Scitech-Mq Pharmaceuticals","route":"/companies/beijing-scitech-mq-pharmaceuticals/"}]}}